TFA对3-乙酰氧基氨基喹唑啉酮2和10与丙烯酸甲酯和丙烯酸叔丁酯竞争反应的影响被解释为支持过渡态几何形状的变化,其中(Q)C O /(酯)C O重叠7b被(Q)C N + H /(酯)C O重叠7c取代(Q =喹唑啉酮)。即使不存在TFA,使用2-三氟甲基取代的3-乙酰氧基氨基喹唑啉酮20和21进行丙烯酸甲酯或丙烯酸叔丁酯的氮杂环化反应也具有(Q)C N /(酯)C O重叠22。
TFA对3-乙酰氧基氨基喹唑啉酮2和10与丙烯酸甲酯和丙烯酸叔丁酯竞争反应的影响被解释为支持过渡态几何形状的变化,其中(Q)C O /(酯)C O重叠7b被(Q)C N + H /(酯)C O重叠7c取代(Q =喹唑啉酮)。即使不存在TFA,使用2-三氟甲基取代的3-乙酰氧基氨基喹唑啉酮20和21进行丙烯酸甲酯或丙烯酸叔丁酯的氮杂环化反应也具有(Q)C N /(酯)C O重叠22。
The present invention relates to compounds of formula (I)
and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.
Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.